Speciality Medicines IPO
Market Sentiment
Market Lot Size
IPO Details
IPO Reservation
Financial Analysis
| Metric | 2024 | 2025 | Oct 2025 |
|---|---|---|---|
| Revenue | 27.66 | 58.54 | 36.93 |
| Expense | 23.10 | 49.85 | 30.80 |
| Profit (PAT) | 2.93 | 8.61 | 6.06 |
| Total Assets | 22.68 | 39.98 | 45.57 |
| Company | P/E | EPS | Market Cap (Cr) |
|---|---|---|---|
| Remus Pharmaceuticals Limited | 12.25 | 65.21 | 15 |
| Trident Lifeline Limited | 27.59 | 10.22 | 18 |
| Mono Pharmacare Limited | 13.87 | 1.75 | 10 |
Promoters: Parth B Goyani and Goyani Sumit Babubhai
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 64,35,796 | 59.28% |
| Promoter Holding Post Issue | 87,85,796 | 43.44% |
Company Information
One of the leading companies,” Speciality Medicines” was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology, and rare diseases. Moreover, the company operates in two ways: (a) contract manufacturing of finished formulations for international markets, and (b) marketing and distribution of sourced specialty pharmaceutical products. Further, the company has around 7 registered products overseas, and 54 products are in the registration process across 5 countries.
| Purpose | Amount (Cr) |
|---|---|
| Setting up of the Research and Development (R&D) Centre | 13.31 |
| Product registration in the international markets | 2.89 |
| Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company | 1.75 |
| To Meet Working Capital Requirements | 12.00 |
| General Corporate Purpose | - |
Resources & Documents
Speciality Medicines Ltd., 913, One World West, S. No. 396, FP 119,, Village- Vejalpur, Ahmadabad City,, Ahmedabad, Gujarat, India,, Ahmedabad, Gujarat, 380051
Understanding Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.
How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.
Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.
Factors that influence GMP:
- Subscription levels — Higher subscription typically drives GMP up
- Market conditions — Bullish markets tend to boost GMP across all IPOs
- Company fundamentals — Strong financials and growth potential attract premium
- Industry sentiment — Positive outlook for the sector can increase demand
- IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP
Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.
Related IPO
No comments yet. Be the first to share your opinion!